No Detail Found!

Efficacy of combined medication of risedronate sodium and selective estrogen receptor modulator on the postmenopausal osteoporosis

Author(s)
Yanhua Deng Department of Nursing, Jingzhou Chinese Medicine Hospital of Hubei Province,Jingzhou, Hubei,China
Lin Li Department of Nursing, Jingzhou Chinese Medicine Hospital of Hubei Province,Jingzhou, Hubei,China
Ceng Li Department of Orthopedics, Jingzhou Chinese Medicine Hospital of Hubei Province,Jingzhou, Hubei,China
FangWang Department of Physical Examination, Jingzhou Chinese Medicine Hospital of Hubei Province,Jingzhou, Hubei,China
Yang Qu Department of Orthopedics Medical Center,the 2,Hospital of Jilin University, Changchun, Jilin, China
Abstract
To evaluate the efficacy of combined medication of risedronate sodium and raloxifene, a selective estrogen receptor modulator (SERM) on the postmenopausal osteoporosis (PMOP). PMOP patients underwent the combined medication of risedronate sodium and raloxifene (SERM, Treatment group), or only medication of risedronate sodium (Control group). After medication, more significant increases were observed in the bone densities of the lumber vertebra (L1-4) and the neck of left femur of patients in the treatment group. Simultaneously, the levels of estrogen and progesterone in serum decreased sharply in the treatment group. After treatment, P1NP and ß-CTX levels in serum decreased significantly in two groups in comparison with the levels prior to treatment, with evident elevations in the levels of BAP and BGP; similarly, ameliorations in the treatment group were much more evident than those in the control group. In addition, significant declines were identified in the VAS scores of two groups after treatment when comparing to the scores prior to the treatment, and the decline in the treatment group was more evident than that in the control group. Combined medication of risedronate sodium and SERM (raloxifene) performs better in treatment of osteoporosis than the single use of risedronate sodium, without the deterioration of adverse effect of medication.
Publication Details
Page(s) 495-498
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 33, Issue: S1, Year: 2020

Request the full text from PASTIC

Keywords
raloxifene, Bone Mineral Density, estrogen replacement therapy, Risedronate sodium, Postmenopausal osteoporosis
References
Metab J. Clin. Endocrinol. . .. , 100(12) : 4662-4668.
Cummings SR,Cosman F,Lewiecki EM .2017 .. , : .
Res. . .. , 32(1) : 3-10.
Qaseem A,Forciea MA,McLean RM .2017 .. , : .
. .Treatment of low bone density or osteoporosis to prevent fractures in men and women: A clinical practice guideline update from the american college of physicians. , 167(12) : 899.
Allen MR,Mcnerny E,Aref M .2017 .Effects of combination treatment with alendronate and raloxifene on skeletal properties in a beagle dog mode. PLoS One, 12(8) : e0181750.
Vandenbroucke A,Luyten FP,Flamaing J .2017 .. , : .
. .Pharmacological treatment of osteoporosis in the oldest old. Clin Interv Aging, 12 : 1065-1077.
Tu KN,Lie JD,Wan C .2018 .Osteoporosis: A review of treatment options. , 43(2) : 92-104.
Qi YJ,Cai J,Guang L .2017 .The clinical effect and mechanism of Jintiange capsule in the treatment of postmenopausal osteoporosis. Chin. J. Endocr. Surg., 9(5) : 404-408.
Sun YG,Ruan XY,Du XP .2016 .Evaluation of the effectiveness of a simple tool for predicting the risk of osteoporotic fracture in screening for abnormal bone mass in postmenopausal women in community. , : .
Gen. Pract. . .. , 19(14) : 1620-1624.
Chavassieux P,Portero-Muzy N,Roux JP,Lambertini M,Mastro LD,Viglietti G .2017 .Ovarian function suppression in premenopausal women with early-stage breast cancer. Curr. Treat. Option Oncol., 18(1) : 4-4668.
Chavassieux P,Portero-Muzy N,Roux JP .2015 .Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women?. , : .
0

Citations

0

Downloads

8

Views